- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Olema Pharmaceuticals Inc Palazestrant Phase 2 Monotherapy Clinical Update Presentation TranscriptOct 23, 2023
- Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference TranscriptAug 09, 2023
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Olema Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit TranscriptFeb 23, 2023
- Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Olema Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Olema Pharmaceuticals Inc at Jefferies London Healthcare Conference TranscriptNov 16, 2022
- Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- Olema Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Olema Pharmaceuticals Inc at Canaccord Genuity Horizons in Oncology Conference (Virtual) TranscriptApr 14, 2022
- Olema Pharmaceuticals Inc to Review the Phase 1 Clinical Data for OP-1250 TranscriptNov 30, 2021
- Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
All right. Let's get started here. Welcome everybody to the Wednesday afternoon of the 41st annual JPMorgan Healthcare Conference. My name is Anupam Rama, I'm one of the Senior Biotech Analyst here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team. Our next presenting company is Olema. And presenting on behalf of the company, we have CEO, Sean Bohen.
Thanks very much, Anupam. Thank you, everybody, for joining us today. It's nice to be in person. This slide is when you all be familiar with forward-looking statements -- there are some in here.
So our objective at Olema oncology is to develop better therapeutic options for cancer, particularly cancers that are current primarily women. So our lead drug and only clinical candidate is OP-1250. It's targets -- the validated target, the estrogen receptor in ER+ breast cancer.
And we have several attributes of OP-1250 that we are looking for to be best in class to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)